1. Clinical Overview
Molecule: Mechanosensitive splice variant of IGF-1 (IGF-1 Ec Isoform), produced locally in muscle after mechanical overload/injury.
Classification: Acute-phase muscle regeneration peptide • Satellite cell activator • Locally-acting IGF-1 isoform • Anti-apoptotic repair molecule • Hypertrophy/recovery peptide
MGF vs IGF-1 LR3
| Property | MGF | IGF-1 LR3 |
|---|
| Primary role | Repair & satellite cell activation | Growth & hypertrophy |
| Timing | Post-injury / post-training | Daily systemic |
| Half-life | Short (minutes–hours) | Long (20–30 hours) |
| Local vs systemic | Local/regional | Systemic |
| Best use | Injury, repair | Hypertrophy, metabolism |
Together, MGF + IGF-1 LR3 form a powerful two-phase anabolic/repair stack replicating natural muscle physiology.
2. Mechanisms of Action
2.1 Satellite Cell Activation (Primary)
One of the strongest known satellite cell activators: muscle stem-cell proliferation, damaged fiber repair, new myonuclei formation. Cannot be replicated by IGF-1 alone.
2.2 Local Muscle Repair Signal
Functions locally/autocrinely: released only in damaged/stressed muscle, signals rapid repair, prevents apoptosis.
2.3 IGF-1 Axis Synergy
MGF → satellite cell activation → IGF-1 LR3 → differentiation + hypertrophy. Gold-standard two-phase sequence.
2.4 Anti-Apoptotic & Protective
Reduces caspase activity, protects cells after overexertion, reduces muscle fibrosis.
2.5 Age-Related Decline Prevention
MGF production declines with age → sarcopenia, slower recovery, reduced stem-cell activity. Supplementation re-establishes youthful repair.
3. Evidence-Supported Applications
3.1 Muscle Injury Recovery
Tears, chronic strains, contusions, post-surgical repair, overtraining damage. Often combined with BPC-157 & TB-500.
3.2 Tendon, Ligament & Joint
Progenitor cell activation, collagen repair, joint soft-tissue healing.
3.3 Hypertrophy & Athletic Development
Post eccentric loading, high-volume workouts, novel training phases. Enhanced lean mass, strength, training frequency capacity.
3.4 Post-Surgical Atrophy Prevention
Mitigates muscle loss after immobilization, orthopedic surgery, long rehab windows.
3.5 Anti-Aging / Sarcopenia
Older adults, frailty, slow recovery, low satellite-cell activity. Counters age-driven anabolic resistance.
4. Administration & Protocols
4.1 IM MGF (Preferred)
Localized: 100–300 mcg IM near target muscle, post-training/injury, 1–2×/day
Injury Repair: 200–300 mcg IM daily × 10–20 days + TB-500 & BPC-157
4.2 SC MGF
200–400 mcg SC daily, post-training window. For larger areas or systemic repair.
4.3 PEG-MGF (Extended Half-Life)
200–400 mcg SC, 2–3×/week. Half-life extended to 12–24 hours via PEGylation.
4.4 Two-Phase MGF → IGF-1 LR3 Protocol
Phase 1 (MGF): 100–300 mcg IM/SC immediately post-training → satellite cell proliferation
Phase 2 (IGF-1 LR3): 20–80 mcg SC 1–2 hours after MGF → hypertrophy & differentiation
Never combine simultaneously — they counter-regulate each other.
5. Combination Therapy (Peptide Protocol Portal Synergy)
MGF + IGF-1 LR3: Gold standard — most powerful hypertrophy + repair stack
MGF + BPC-157 + TB-500: Ultimate injury-repair triad (stem cells + angiogenesis + remodeling)
MGF + CJC-1295 + GHRPs: Enhanced GH environment + IGF axis + recovery
MGF + SS-31 / MOTS-c: Mitochondrial repair for athletes/older adults
MGF + AOD-9604: Body recomposition — fat loss + muscle retention
6. Clinical Decision Trees
Decision Tree 1 — Should MGF Be Used?
Recovering from muscle injury? → YES
Goal: hypertrophy or rapid recovery? → YES
Post-surgery with atrophy risk? → YES
Elderly with sarcopenia? → YES
Systemic fat loss priority? → MGF is secondary
Prefers IM over SC? → IM gives best localized benefits
Decision Tree 2 — Dose Selection
Localized injury/surgery → 200–300 mcg IM daily
Post-training hypertrophy → 100–200 mcg IM post-workout
Systemic recovery → 200–400 mcg SC daily
Convenience (PEG-MGF) → 200–400 mcg SC 2–3×/week
7. Integrated Treatment Archetypes
Archetype A — Muscle Tear / Sports Injury
Systemic: MGF 200–300 mcg IM daily + TB-500 weekly + BPC-157 daily + NAD+
Outcome: Accelerated regeneration, reduced scar formation.
Archetype B — Hypertrophy / Strength
Systemic: MGF post-training + IGF-1 LR3 1–2 hrs after + CJC-1295/Ipamorelin nightly
Outcome: Superior hypertrophy and rapid repair.
Archetype C — Anti-Aging / Sarcopenia
Systemic: MGF 200 mcg SC daily + MOTS-c weekly + SS-31 + RECOVER™
Outcome: Restored strength, vitality, muscle tone.
Archetype D — Post-Surgical Preservation
Systemic: MGF daily SC/IM + TB-500 weekly + BPC-157 daily + IGF-1 LR3 low dose
Outcome: Reduced atrophy, faster return-to-function.
8. Expected Clinical Timeline
Day 1–3: Improved soreness, reduced stiffness
Week 1–2: Faster recovery
Week 2–4: Visible hypertrophy
Week 4–8: Significant functional gains
Long-term: Enhanced muscle density and resilience
9. Contraindications
Absolute
- Active cancer (especially IGF-driven)
- Pregnancy
- Breastfeeding
Relative
- Diabetes (monitor glucose)
- Severe cardiac disease
- Retinopathy
- Uncontrolled hypertension
10. Adverse Effects
Most common: injection site soreness, water retention (mild), temporary lethargy, headache. Less common: hypoglycemia (with IGF-1 LR3), joint aches, appetite fluctuations.
11. Monitoring
- IGF-1 levels
- Fasting glucose
- Muscle strength metrics
- Injury healing progression
- Body composition
- Training tolerance
Legal Disclaimer
This document is provided solely for educational and informational purposes. MGF and other peptides are not FDA-approved drugs. Peptide Protocol Portal makes no representations or warranties. By using this document, the reader agrees that Peptide Protocol Portal shall not be held liable. Use at your own risk.
References — MGF Clinical Reference Guide
Foundational Discovery & Identification
1. Yang, S. Y., Goldspink, G. IGF-1 isoforms in muscle growth and repair. Acta Physiol Scand, 167(4), 301–309 (1999).
2. Goldspink, G. Gene expression in muscle adaptation: MGF. Med Sci Sports Exerc, 35(5), 716–723 (2003).
3. Hill, M., & Goldspink, G. MGF expression following exercise. J Physiology, 548(2), 769–780 (2003).
4. Yang, S., et al. MGF mRNA as early response to mechanical stimuli. J Physiology, 516(2), 573–583 (1999).
Hypertrophy, Repair & Satellite Cells
5. McKoy, G., et al. MGF activates satellite cells. J Physiology, 547(2), 531–538 (2003).
6. Adams, G. R. IGF-1 and MGF in skeletal hypertrophy. J Endocrinology, 152(1), 1–2 (1997).
7. Musarò, A., & Rosenthal, N. IGF-1 isoforms in muscle regeneration. Nature, 400(6744), 581–585 (1999).
8. Zeng, M., et al. MGF supports myotube survival. Mol Cell Biochem, 337(1–2), 55–63 (2010).
9. Philippou, A., et al. MGF vs IGF-1Ea in resistance exercise. Am J Physiol Endocrinol Metab, 284(4), E627–E633 (2003).
Aging & Sarcopenia
10. O'Neill, B. T., et al. Declining IGF-1 isoforms in aging muscle. Aging Cell, 15(3), 439–449 (2016).
11. Kandalla, P. K., et al. Age-related MGF downregulation. Mech Ageing Dev, 134(7–8), 356–366 (2013).
12. Barton-Davis, E. R., et al. MGF reverses age-related wasting. Nature, 402, 200–203 (1999).
Tendon & Connective Tissue
13. Heinemeier, K. M., et al. MGF in tendons under loading. J Appl Physiol, 106(2), 575–581 (2009).
14. Paerhati, S., et al. MGF improves tendon fibroblast proliferation. Connect Tissue Res, 54(5), 339–347 (2013).
Bone & Orthopedic
15. Yi, C., et al. MGF promotes osteoblast proliferation. J Bone Miner Res, 18(4), 703–711 (2003).
16. Khorshidi, M., et al. MGF improves bone repair. Bone, 45(5), 885–893 (2009).
17. Brodt, M. D., et al. Mechano-sensitive IGF-1 isoforms in skeletal tissue. J Bone Miner Res, 26(1), 131–140 (2011).
Neuroprotection & CNS
18. Dluzniewska, J., et al. MGF protects neurons from β-amyloid. J Neurochem, 91(1), 34–43 (2004).
19. D'Ercole, A. J., et al. IGF-1 isoforms in CNS neuroregeneration. Trends Neurosci, 25(8), 349–355 (2002).
20. Quesada, A., et al. MGF enhances neuronal survival after ischemia. Neurosci Lett, 423(3), 181–185 (2007).
Cardiac & Anti-Apoptotic
21. Shavlakadze, T., Grounds, M. MGF in cardiac tissue repair. Circulation, 112(20), 3124–3133 (2005).
22. Siwik, D. A., et al. MGF reduces cardiomyocyte apoptosis. Cardiovasc Res, 89(1), 67–75 (2011).
23. Loudon, B. L., et al. IGF-1 isoforms in cardiovascular tissue. J Mol Cell Cardiol, 49(3), 398–404 (2010).
Mechanotransduction & Gene Expression
24. Carroll, A. M., & Goldspink, G. MGF as mechanotransduction gene. Pflügers Archiv, 452(3), 332–340 (2006).
25. Bickel, C. S., et al. IGF-1 splice variants after resistance training. Eur J Appl Physiol, 101(3), 353–360 (2007).
Pharmacologic & Delivery
26. Adams, G. R. MGF peptide analogues in regenerative therapy. Sports Medicine, 34(14), 953–970 (2004).
27. Kandalla, P. K., et al. MGF peptide delivery enhances regeneration. Growth Horm IGF Res, 22(3–4), 143–150 (2012).
28. Liu, J. P., & Baker, J. IGF-1 receptor dependence of MGF. Endocrine Reviews, 26(5), 916–944 (2005).
Metabolic & Systemic
29. Clemmons, D. R. IGF-1 in muscle and metabolic health. Endocrine Reviews, 34(1), 1–19 (2013).
30. Yakar, S., et al. IGF-1 regulates metabolic function. PNAS, 98(18), 10403–10408 (2001).